A therapeutic trial of radiation therapy with vincristine, etoposide, and procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group study (E2392)

被引：10

作者：

Hellman, R

Neuberg, DS

Wagner, H

Gunnet, M

Robins, HI

Karp, D

Flynn, P

Adams, G

机构：

[1] Lawrence & Mem Hosp, Community Canc Ctr, New London, CT 06320 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[4] Univ Connecticut, Ctr Hlth, Farmington, CT USA

[5] Univ Wisconsin, Madison, WI 53706 USA

[6] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA

[7] Metro Minneapolis CCOP, Minneapolis, MN USA

[8] Univ Minnesota, Minneapolis, MN 55455 USA

来源：

JOURNAL OF NEURO-ONCOLOGY | 1998年 / 37卷 / 01期

关键词：

glioblastoma multiforme; anaplastic astrocytoma; high grade glioma; etoposide (VP-16); procarbazine; vincristine;

D O I：

10.1023/A:1005867520788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

引用

页码：55 / 62

页数：8

共 17 条

[1]

[Anonymous], 1989, Analysis of binary data

[2]

COX DR, 1972, J R STAT SOC B, V34, P187

[3]

RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS [J].

CURRAN, WJ ;

SCOTT, CB ;

HORTON, J ;

NELSON, JS ;

WEINSTEIN, AS ;

FISCHBACH, AJ ;

CHANG, CH ;

ROTMAN, M ;

ASBELL, SO ;

KRISCH, RE ;

NELSON, DF .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) :704-710

[4]

FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO

[5]

2-S

[6]

GREEN SB, 1983, CANCER TREAT REP, V67, P121

[7]

HELLMAN R, 1994, P AN M AM SOC CLIN, V13, P181

[8]

HELLMAN RM, 1990, J NEURO-ONCOL, V8, P163

[9]

LACK OF POTENTIATION OF VINCRISTINE-INDUCED NEUROTOXICITY BY VP-16-213 [J].

JACKSON, DV ;

WELLS, HB ;

WHITE, DR ;

MUSS, HB ;

RICHARDS, F ;

COOPER, MR ;

STUART, JJ ;

POPE, EK ;

SPURR, CL .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1983, 6 (03) :327-330

[10]

SYNERGISTIC ANTITUMOR-ACTIVITY OF VINCRISTINE AND VP-16-213 [J].

JACKSON, DV ;

LONG, TR ;

TRAHEY, TF ;

MORGAN, TM .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 13 (03) :176-180

← 1 2 →